Can Fluconazole Be Used to Treat Non-Resistant Candida ( Candidozyma ) auris Infections? Preclinical Pharmacokinetic/Pharmacodynamic Data From a Galleria mellonella Infection Model
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiag182 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Vasiliki Kroustali und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Gree…. Hauptthemen laut MEDLINE: Fluconazole, Antifungal Agents, Candidiasis, Candida auris. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Azole therapy is currently not used against Candida auris infections. Although fluconazole resistance is prevalent, 10% to 45% of isolates among clades remain non-resistant (minimum inhibitory concentrations [MICs] <32 mg/L). We evaluated fluconazole pharmacokinetics/pharmacodynamics against these isolates using a Galleria mellonella model.
Methods
Nine C. auris isolates representing 5 clades and MICs of 1 to 128 mg/L were studied, and 4 Candida albicans isolates were included for model validation. Larvae were infected with lethal inocula and treated for 4 days with human-equivalent fluconazole doses. Efficacy endpoints were 24-hour change in fungal burden and 7-day survival. Free-drug 24-hour area under the concentration-time curve divided by the MIC (fAUC0–24/MIC) target was derived by a sigmoidal Emax model, and Monte Carlo simulations estimated the probability of target attainment.
Results
For C. albicans, the Clinical and Laboratory Standards Institute (CLSI) fAUC0–24/MIC corresponding to EI50 for 24-hour fungal burden reduction was 35.5, consistent with murine models. EI90 survival targets were 76.5 (CLSI) and 68.9 (European Committee on Antimicrobial Susceptibility Testing) fAUC0-24/MIC, supporting the clinical breakpoints and validating the model. For C. auris, EI90 targets for survival were 93.2 (CLSI) and 63.2 (European Committee on Antimicrobial Susceptibility Testing) fAUC0-24/MIC, and probabilities of target attainment >95% were found for isolates with MICs up to 2, 4, and 8 mg/L with fluconazole doses of 400, 800, and 1200 mg/d, respectively.
Conclusions
Fluconazole demonstrated similar in vivo activity against C. auris and C. albicans. Putative wild type isolates with MICs ≤8 mg/L may be treatable with 1200 mg/d. Clinical studies are needed to verify the efficacy of fluconazole against C. auris.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Microbiology Laboratory, "Attikon" University General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
ORCID-Profile: Vasiliki Kroustali, Joseph Meletiadis
Zitieren
APA
Kroustali, V., Pournaras, S., & Meletiadis, J. (2026). Can Fluconazole Be Used to Treat Non-Resistant Candida ( Candidozyma ) auris Infections? Preclinical Pharmacokinetic/Pharmacodynamic Data From a Galleria mellonella Infection Model. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiag182
Vancouver
Kroustali V, Pournaras S, Meletiadis J. Can Fluconazole Be Used to Treat Non-Resistant Candida ( Candidozyma ) auris Infections? Preclinical Pharmacokinetic/Pharmacodynamic Data From a Galleria mellonella Infection Model. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiag182
BibTeX
@article{Kroustali2026,
author = {Kroustali, Vasiliki and Pournaras, Spyros and Meletiadis, Joseph},
title = {Can Fluconazole Be Used to Treat Non-Resistant Candida ( Candidozyma ) auris Infections? Preclinical Pharmacokinetic/Pharmacodynamic Data From a Galleria mellonella Infection Model},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiag182}
}
EUVIMED